Aldeyra Therapeutics (ALDX) Research & Development (2013 - 2026)
Aldeyra Therapeutics (ALDX) posted Research & Development of $2.4 million for Q1 2026, down 44.01% on a QoQ basis from $4.3 million in Q4 2025, and down 67.54% year-over-year from $7.4 million in Q1 2025.
Aldeyra Therapeutics (ALDX) Research & Development (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics' Research & Development history runs 14 years deep, the most recent figure standing at $2.4 million for Q1 2026.
- Quarterly Research & Development fell 67.54% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.6 million (down 58.25% YoY) and the FY2025 annual result came in at $25.7 million, down 46.78% from the prior year.
- Research & Development was $2.4 million for Q1 2026 at Aldeyra Therapeutics, down from $4.3 million in the prior quarter.
- Across five years, Research & Development topped out at $15.0 million in Q2 2024 and bottomed at $2.4 million in Q1 2026.
- A 5-year average of $9.0 million and a median of $8.5 million in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development jumped 240.37% — and 2025, when it plunged 70.58%.
- Aldeyra Therapeutics' Research & Development stood at $9.0 million in 2022, then slumped by 52.04% to $4.3 million in 2023, then soared by 240.37% to $14.6 million in 2024, then plunged by 70.58% to $4.3 million in 2025, then plunged by 44.01% to $2.4 million in 2026.
- Business Quant data shows ALDX's Research & Development at $2.4 million in Q1 2026, $4.3 million in Q4 2025, and $5.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,933.35 Bn | 1,933.29 Bn | - | - |
| 3 | Akari Therapeutics | 1,063.56 Bn | 1,063.56 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 468.54 Bn | 463.75 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.20 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 63.57 Bn | 63.57 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Alnylam Pharmaceuticals | 37.75 Bn | 34.74 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Aldeyra Therapeutics | 94.70 Mn | 94.70 Mn | - | 2.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.41 Mn |
| Dec 31, 2025 | 4.30 Mn |
| Sep 30, 2025 | 5.43 Mn |
| Jun 30, 2025 | 8.51 Mn |
| Mar 31, 2025 | 7.42 Mn |
| Dec 31, 2024 | 14.63 Mn |
| Sep 30, 2024 | 12.44 Mn |
| Jun 30, 2024 | 14.97 Mn |
| Mar 31, 2024 | 6.18 Mn |
| Dec 31, 2023 | 4.30 Mn |
| Sep 30, 2023 | 6.96 Mn |
| Jun 30, 2023 | 6.96 Mn |
| Mar 31, 2023 | 11.24 Mn |
| Dec 31, 2022 | 8.96 Mn |
| Sep 30, 2022 | 11.54 Mn |
| Jun 30, 2022 | 14.57 Mn |
| Mar 31, 2022 | 12.23 Mn |
| Dec 31, 2021 | 12.84 Mn |
| Sep 30, 2021 | 12.89 Mn |
| Jun 30, 2021 | 11.47 Mn |